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What is known about topic: 
 Podoconiosis (non-filarial elephantiasis) is a tropical skin disease sometimes known 
as “Mossy Foot” due to moss-like skin eruptions. It is caused by irritant soil 
particulates and pathogens entering the plantar skin via skin breaches affecting the 
lower leg lymphatics. It is not curable but is treatable.  
 The current podoconiosis skin care treatment regimen reduces clinical disease stage 
and oedema, improves skin condition and quality of life but may not be optimum and 
requires 6 litres of scarce water resource.  
 What does this add:    
 This is the first published RCT evaluating podoconiosis skin treatment regimens 
using quantitative measures of skin barrier function (SBF).  
 A new treatment regimen, incorporating 2% glycerine (v/v) in 1/6 of the current 
water volume, significantly improved SBF and clinical disease presentation 
compared to the current regimen.  
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Abstract  
Background 
Podoconiosis affects an estimated 3 million people in Ethiopia with a further 19 million at 
risk. Volcanic soil and pathogens enter skin breaches in the feet causing inflammation, 
lymphoedema and hyperkeratosis. There is no robust evidence on optimal podoconiosis skin 
care regimens to improve SBF.  
Objectives  
To evaluate the effectiveness of a new, low-cost, evidence-based intervention to improve 
SBF in the lower limbs of those with podoconiosis.  
Methods  
A randomized control trial (RCT) was conducted over 3 months in two podoconiosis clinics 
(n=193). The intervention comprised 2% glycerine (v/v) added to a reduced amount of 
soaking water. The control group received the current skin care regimen. Primary outcome 
measures were trans-epidermal water loss (TEWL) and stratum corneum hydration (SCH) at 
four specific sites on the lower limbs. 
Results  
Improvement in SBF was observed in both groups across all measurement sites and time 
points, although this was significantly greater in the experimental group. TEWL reduced in 
both groups at all sites. For example, on top of the foot the estimated group difference in 
TEWL at the fourth visit was 1.751 (SE=0.0390) in favour of the experimental group 
(t=3.154, df=189.580, p=0.002, 95% CI (0.0656 to 2.846)), indicating a greater reduction in 
the experimental group. Similarly, at the same site the estimated group difference in SCH at 
the fourth visit was -2.041(CI=0.572) in favour of the experimental group (t=-3.565, 
df=186.739, p=<0.001), 95% CI (-3.168 to -0.911)), indicating a greater increase in the 
experimental group. There were also significantly greater reductions in odour, number of 
wounds and largest foot circumference in the experimental compared to the control group.  
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Conclusions 
The addition of 2% glycerine (v/v) to a reduced volume (83% reduction) of soaking water 
significantly improved SBF (Registered trial NCT02839772). 
Introduction  
Podoconiosis is a non-infectious skin disease resulting in bilateral and usually asymmetric 
lymphoedema below the knee1. It is found in over 20 countries across tropical Africa, Central 
America, and northern India2. Prevalence data is unavailable in most countries except in 
Ethiopia. The minerals smectite, mica and quartz (crystalline silica) within alkaline volcanic 
soil are associated with areas of prevalence3. Due to poverty or culture, subsistence farmers 
and others may not wear shoes or those providing inadequate protection. Plantar stratum 
corneum (SC) thickens, dries and becomes extremely brittle, leading to deep cracks and 
fissures allowing soil particles and bacteria to enter, triggering the inflammatory process4.  
Water is essential to cleanse the skin surface of soil and pathogens, to help maintain healthy 
SBF. This is a major challenge in the developing world, where water is typically carried to 
homes from remote stand pipes, wells or rivers. The use of this precious resource for washing 
skin is a relatively low priority, resulting in poor foot hygiene. Subsequent oedema disrupts 
superficial lymphatic drainage, causing further oedema and stress on deeper lymphatics. If 
overloaded, this secondary drainage system can fail, causing lymphoedematous feet and 
legs5. The high protein content of static lymph fluid in tissues leads to trophic skin changes, 
including hair loss, xerosis, hyperkeratosis, adipose tissue deposition and papillomatiasis6.  
Figure 1 proposes a cyclical pathogenic model for podoconiosis induction and propagation. 
Without therapeutic intervention, the cycle continues, with worsening lymphoedema and skin 
change. Disease progression has five stages of severity (5=most severe)7. Transforming 
growth factor beta 1 (TGF-β1) has a pathogenic role in the disease and oxidative stress a 
lesser role8. The disease is thought to be T cell-mediated with high (63%) hereditability9.  
Severe macro- and micro-economic effects are caused by significant social stigmatisation and 
episodic severe leg pain from adenolymphangitis (ADL)10. Acute attacks of ADL cause leg 
inflammation and inguinal lymphadenopathy. This results in lost work days with subsequent 
loss of family income. The estimated cost in one region in Ethiopia (population of 1.5 
million) was estimated at US$ 16 million a year. Stigmatisation is widespread due to the 
appearance of the disease, unpleasant odour and the unfounded fear of infection.  Patients 
report that they are unable to marry, are shunned by others and excluded from social events11. 
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This ostracism increases as the disease progresses. Wearing shoes provides only partial 
protection. One large study found heel cracks and foot trauma present regardless of shoe 
type12. Maintaining SBF health and effective washing of feet/legs is, therefore, essential in 
podoconiosis prevention.  
 
The current treatment regimen taught in “Action on Podoconiosis and Integrated 
Development Organisation” (APIDO) clinics consists of washing feet/legs daily in soapy 
water, a 30 minute soak in 6 litres of water with 0.0125% (v/v) sodium hypochlorite 
(NaOCl), air drying and application of petrolatum jelly to augment SBF and reduce friction13. 
Surfactant action removes pathogens/soil, while the soak hydrates the SC (decreasing its 
elastic modulus, creating a pliable structure less likely to crack or split) and NaOCl reduces 
pathogen load. Whitfield’s ointment is used, where appropriate, to treat fungal infection. A 
one  year non-comparative longitudinal study using a similar regimen was effective in 
reducing disease clinical stage, oedema, and improving Quality of Life scores (n=27)14. No 
previous RCTs assessing treatment regimens for this disease were identified. 
 
We hypothesised that addition of low levels of humectant to the regimen would increase SC 
hygroscopicity improving SBF and, ultimately, clinical outcome. Glycerine was chosen 
because of its wide range of efficacy, low cost and availability even in resource-poor settings. 
In Ethiopia it can be obtained easily in road-side kiosks for around 50 pence/100ml). The 
glycerine concentration chosen (2% v/v) was based on a balance between cost and previous 
studies showing efficacy at this concentration15-18. Fluhr15 identified glycerine-related skin 
benefits as improved SCH, SBF, desmosomal degradation and skin mechanics, inhibition of 
SC lipid-phase transition, accelerated wound healing, reduced irritation and some 
antimicrobial efficacy. To conserve glycerine and water, we reduced the wash-water volume 
from 6 to 1 litre (i.e., by 83%).  
Materials and Methods   
Study design and population 
The null hypothesis was that an evidence-based skin care intervention which added 2% 
glycerine to the current skin regimen used to treat Ethiopian podoconiosis patients would not 
improve SBF and disease-related quality of life, compared to the current regimen. The study 
used an RCT parallel-group design. Data were collected from two APIDO clinics in the 
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Gamo Gofa zone, Southern Ethiopia, January-August 2014. Clinics were chosen within 
similar socio-economic populations and geographical areas (with volcanic soil, high rainfall 
and elevations >1600 meters above sea-level). Inclusion criteria were previously untreated 
patients with podoconiosis (determined by the experienced clinic nurses), over 18 years able 
to give informed consent.  
Sample size and selection  
Computerised stratification of the sample ensured similar gender numbers and those with 
mild/moderate (Stages 1-3) to severe disease (Stages 4-5)7; this allowed variance between 
these factors to be determined. The study was powered to detect a difference between the 
treatment groups. Based on the pilot study results19, an effect size of around 0.72 was 
expected for TEWL (primary outcome measure). To achieve a power of 80% (2-sided t-test) 
with a 5% significance level, 64 participants were required, divided equally between the two 
treatment groups. To allow detection of possible smaller effect sizes on other secondary 
outcome measures, a target sample size of 200 was chosen. Participants were allocated 
randomly to groups using a computer-generated sequential system based on clinic, gender 
and disease severity. Randomisation was explained to participants as their allocation to a 
group using the current effective treatment or another using an extra harmless product. Four 
containers were placed in each clinic (labelled by gender/disease severity) containing 
individually-coded sealed opaque envelopes opened sequentially by the nurse to reveal group 
allocation.  
Ethical approval 
Ethical approval for the study was obtained from the University of Hull, UK (Approval letter 
reference 125, 29.11.13) and Sodo University, Ethiopia (24/214/2013). An explanation of the 
study was read out by the clinic nurse to each potential participant and any clarifying 
questions answered. As most were illiterate, those willing to take part signed or marked their 
agreement with a cross or ink mark from their index finger, witnessed, signed and dated by 
the clinic social worker.  
Study groups and Intervention tested 
Each individual was taught (verbally and by demonstration) initially and at each monthly 
visit how to treat their feet/legs according to their group. Control group subjects continued 
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with the daily skin treatment used currently in APIDO clinics (see Introduction). In the 
experimental group: 
 1 litre of water (only) was used for feet soaking and splashing lower legs.  
 20ml glycerine was added to provide a 2% (v/v) dilution. 
Measures used 
Primary outcome measures of TEWL and SCH were measured using portable, wireless, non-
invasive probes (Delfin Technologies Ltd., Finland). TEWL (water flux across the SC, 
measured in grams of water per square meter, per hour) was measured with a VapoMeter® 
closed-chamber evaporimeter and SCH (reflecting SC water content) was measured in 
arbitrary units using a MoistureMeter SC® probe (based on electrical capacitance). These 
instruments were used previously by one of the authors (PM) to successfully measure SBF in 
those with podoconiosis in rural Ethiopia4. Measurements were taken at three sites – on the 
outer, lower leg (8cm below the fibula head (top), 8cm above the external malleolus (base) at 
mid-point between these sites and the top of the foot (similar to Ferguson et al.4).  
 
In each site, SCH measures were made in triplicate (recording the mean). Single TEWL 
measures were recorded. With both of these objective instrumental measurements, it is 
critical to minimise interference from environmental artefacts. In line with the 
manufacturer’s20 and other published guidelines21, therefore, measurements were restricted to 
times of the day when ambient temperature was lower, and patients asked to rest and 
equilibrate for at least 20 minutes, with measurement sites exposed. This process was aided 
by the automatic recording of ambient temperature and humidity by the VapoMeter®. 
Measurements of TEWL are particularly challenging in external environments. The use of a 
closed-chamber evaporimeter proved to be critical in reducing local atmospheric perturbation 
and resulting measurement noise (as per Ferguson et al.4).  
 
Other measures recorded were: stage of podoconiosis, trophic changes (mossy/papillomatosis 
changes present/absent), malodour (if detected on foot/leg by clinic nurse), number of 
wounds, work days lost due to ADL (defined as an episode of inflammatory pain associated 
with the lymph nodes within a lymphoedematous leg which led patients to be 
bedridden/unable to work), largest leg and foot circumferences. The Amharic Dermatology 
Life Quality Index (ADLQI) was used which has been validated for use in those with 
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podoconiosis22. The ten questions assess aspects of an individual’s disease-related quality of 
life. The maximum score of 3 for each question indicates that the disease has a high impact, 2 
a lot of impact, 1 a little and 0 none or the question is irrelevant.    
Data collection 
The qualified nurses and social workers who had worked at each clinic for at least 1 year 
received an initial 5 hour standardised training session provided by the Principal Investigator 
(PI). This included practising measuring the liquids used in the trial, using the instruments 
and completing the data forms under PI supervision. Due to high rates of illiteracy, ADLQI 
questions were read out to individual participants by the clinic nurse.  
 
A local nurse (with a Masters Degree in Public Health, studying podoconiosis, visited each 
clinic to monitor and review data collection and participant treatment at least seven times 
across the 7 month trial period. The PI also directly monitored staff at each clinic, their 
teaching of participants and data collection at weeks 1 (each day for 5 days) and then at 
weeks, 10, 17, and 24. 
 
Baseline data were collected prior to intervention (Visit 1) and data were then collected 
monthly for three months (Visits 2-4).  
Data Analysis  
The data analytic plan was developed a priori. Data were entered into SPSS 22.0 (SPSS Inc., 
Chicago, IL., USA) a statistical package and checked for outliers and completeness prior to 
analysis. Mixed multi-level modelling was used for continuous outcome measures. For each 
such measure, the change from baseline at Visits 2-4 was calculated and used as the 
dependent variable in the analytic model. Generalised estimating equations (GEES) were 
used for discrete, categorical or binary outcome measures. For each such measure, the change 
from baseline at Visits 2-4 was calculated and used as the dependent variable in the model. 
The variables controlled for each outcome measure model were group, clinic, gender, initial 
stage of podoconiosis (Visit 1), side (right/left) of leg and the value of corresponding 
measures at Visit 1. A group-by-time interaction was included in the model to allow the 
group difference, if any, to vary in time.  
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Results 
193 participants enrolled onto the study; (97 in the control group and 96 in the experimental 
group. All completed except one male control group patient with mild/moderate disease who 
did not attend Visit 4. Details are in the Consort Flow Chart (Figure 2). All legs with clinical 
signs of podoconiosis were used as the unit for analysis (n=383). Three participants (1.5%) 
had only one of their legs/feet with clinical signs of podoconiosis. Twenty five participants 
(12.9%) had different stages of podoconiosis in each of their legs, (moderate/less severe 
versus severe). No adverse treatment effects were noted. 
Profile of participants at baseline 
Table 1 provides a demographic profile of patients at baseline.  
Trans-Epidermal Water Loss 
Baseline mean TEWL values in both groups were greatest on the top of feet (weaker SBF) 
and decreased progressively up the lower leg (indicating stronger SBF; Table 2). Mean 
TEWL values in lower legs/feet sites reduced in both groups at Visits 2-4, although the 
reduction was greater in the experimental group (highly significant group difference for all 
legs/feet sites at Visit 4), (Table 3, Figure 3). At all points at Visits 2-4 TEWL reduction was 
greater in right legs and highly statistically significant. At the top of the lower leg the 
difference was (t=-3.415, df=186.089, p=0.001, 95% CI=(-0.574to-0.154)), at mid-point (t=-
2.588, df=187.075, p=0.010, 95% CI=-0.645 to -0.087), at base (t=-2.616, df=189.834, 
p=0.010, 95% CI=-0.595 to 0.083) and on the foot (t=-2.570, df=189.489, p=0.011, 95% 
CI=-0.625 to-0.082) . 
Stratum corneum hydration  
Baseline mean SCH was lower at the base of the leg and top of the feet increasing 
progressively up the lower leg (Table 4). Mean SCH values at all points on the lower 
legs/feet increased in both groups over Visits 2-4, although the increase was greater in the 
experimental group (highly significant), (Table 5, Figure 4).There was no significant 
difference in SCH between right and left legs except at the base of the lower leg (nearing 
significance) (t=1.916, df=180.987, p=0.057, 95% CI (-0.654 to 0.010)). 
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Stage of podoconiosis  
At baseline, 176 legs (45.5%) displayed severe disease (Stages 4-5). By Visit 4, this number 
had decreased to 50 legs (10.6%). Similarly, at baseline, 227 legs (54.5%) displayed 
mild/moderate disease (Stages 1-3). By Visit 4, this number had increased to 320 legs (89.3-
5%). Together, these results indicate clinical improvement due to the two treatment regimens 
based on the description of stages. There was no significant treatment group difference at 
Visit 4 (Log odds ratio=0.452, (SE=0.255), Wald chi square=3.138, df=1, p=0.076, 95% CI (-
0.048 to 0.952)) nor stage difference between right/left legs.  
Trophic (“Mossy”) skin changes   
At baseline, trophic skin changes were present in 153 (79.3%) right legs/feet and in 156 
(80.8%) left legs/feet. By Visit 4, trophic changes were reduced and present in 120 (62.5%) 
right legs/feet and 117 (60.9%) left legs/feet: however, there was neither a significant 
treatment group difference at Visit 4 nor between right/left legs.   
Odour  
At baseline, odour was present in 114 (59.1%) of legs/feet. By Visit 4, odour was reduced 
and present in only 2 right legs/feet (1%) and 1 left leg/foot (0.5%). The odds of leg odour 
being present at Visits 2,3 and 4 was significantly less in the experimental group (Log odds 
ratio=-0.866, (SE=0.401), Wald chi square=4.67, df=1, p=0.031, 95% CI (-1.652 to -0.080)). 
However, the group difference was not clinically significant because the numbers with leg 
odour in each group reduced to almost zero.  
Number of wounds   
At baseline, 105 (54.4% of participants had 4 wounds (all skin breaches and all areas of 
fungal infection on the legs/feet). The experimental treatment led to significantly fewer 
wounds present on legs/feet at Visits 2-4 (significant (p<0.05) group difference). Those in the 
experimental group were expected to have fewer wounds (group ratio estimate=2.062 
(SE=0.741), Wald chi-square=7.745, df=1, p=0.005, 95% CI (0.610 to 3.514)). As most 
participants at the fourth visit had no wounds, the group difference was clinically 
insignificant.  
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Number of days of work lost in previous month due to 
adenolymphangitis (ADL) 
At baseline, the mean number of work days lost in the previous month due to ADL was 4.56 
for the control group and 4.44 for the experimental group.  The group ratio in the expected 
number of days lost at Visit 4 was not significant (group ratio estimate=2.090, (SE=1.102), 
df=1, p=0.058, 95% CI (-0.069 to 4.250)); neither was the difference clinically significant as 
no participants lost any work days in the previous month due to ADL.   
Correlation between days lost due to adenolymphangitis and number of 
wounds 
A Spearman’s correlation at baseline was 0.252, at the second visit 0.306, the third 0.291 and 
the fourth 0.265. This indicated that at all time points there was a weak although highly 
significant correlation (p=<0.001) between the number of lower leg/foot wounds totalled over 
both legs and the number of days participants were unable to work due to ADL for Visits 2, 3 
and 4. 
Largest lower leg circumference  
In the control group the largest lower leg circumference reduced over the study period by 
3.8cm (32.1cm to 28.3cm) and in the experimental group by 4.2cm (32.0cm to 27.8cm). The 
between group treatment difference was not significant (t=1.416, df=185.386, p=0.158, 95% 
CI (-0.113 to 0.690). 
Largest foot circumference  
In the control group, the mean foot circumference reduced over the study period by 2.4cm 
(27.5cm to 25.1cm). The reduction was greater in the experimental group (by 3cm (27.7cm to 
24.7cm). The treatment group difference was highly statistically significant (t=3.550, 
df=169.916, p=<0.001, 95% CI (0.255 to 0.895). The reduction in circumference was greater 
in the right foot (highly significant) (t=-3.270, df=152.994, p=0.001, 95% CI (-0.239 to 
0.059)). 
Amharic Dermatology Life Quality Index (ADLQI) 
The mean ADLQI reduced in both groups over the study period indicating an improved self-
assessed disease-related quality of life. In the control group, the mean ADLQI reduced from 
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21.6 to 4.1 (an improvement of 17.5 points). In the experimental group, the mean ADLQI 
reduced from 21.1 to 3.9 (an improvement of 17.2 points). The estimated group difference at 
Visit 4 was not statistically significant (t=-0.117, df=178.814, p=0.907, 95% CI (-1.129 to 
1.002)).  
Discussion 
To our knowledge, this is the first RCT to study podoconiosis skin care regimens and the 
largest to use a dilution of only 2% glycerine to improve SBF. As hypothesised, the addition 
of 2% glycerine (v/v) to a significantly lower volume of soaking water led to significant 
incremental improvements in SBF in the lower legs and feet of those with podoconiosis. This 
was evident in significantly higher recorded values of SCH and lower recorded values of 
TEWL in skin on the legs and feet of those receiving the experimental versus the current 
treatment regime. This was accompanied by significantly greater reductions in malodour, 
number of wounds and largest circumference of foot in the experimental group compared to 
the control group. No adverse effects were reported.  
 
Ferguson et al.4 measured SBF in those with podoconiosis versus matched control subjects in 
a previous non-intervention study. They reported significantly lower levels of SCH in the 
feet/lower legs of those with podoconiosis, indicating a greater propensity to SC dryness and 
cracking for those with the disease (hence, a higher risk of reactive soil/pathogens entering 
foot tissue). This current study builds upon these insights and demonstrates conclusively the 
central role of compromised SBF in the induction and propagation of podoconiosis. There is 
no other explanation for the relatively acute significant effect of only 2% glycerine (v/v) in a 
simple water soak on both objective SBF measures and clinical outcome in this chronic 
lymphoedematous condition.  
 
We propose a therapeutic model centred around increasing SC hygroscopicity and the 
cascade of ensuing events summarised by Rawlings and Matts23, including; i) an immediate 
reduction in the SC elastic modulus, resulting in a softer, more flexible substrate less prone to 
cracking/splitting; ii) longevity of SCH, activating desquamatory enzymes in previously dry 
SC, leading to a significantly thinner, more compact SC over time; iii) a reduction in 
inflammatory process, leading to a more mature, efficient SC and iv) ultimately, restoration 
of healthy SBF, better able to prevent ingress of irritant soil/pathogens into tissue. 
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Sikorski et al.14 investigated the effect of a similar skin hygiene regimen in podoconiosis 
patients vs a control group over 1 year. Despite this current study being only 3 months in 
length, we report higher reductions in largest lower leg circumference (-4.0cm and -4.1cm in 
this study vs 2.0cm for Sikorski et al.14) and a greater improvement in ADLQI score (17.1 
and 17.5 points in this study vs 15.0 Sikorski et al.14). We cannot account for this difference 
in response but hypothesise that this may be due to different study populations, locations, 
climate or skin regimen compliance.  
 
In this current 3 month intervention study, 62.7% of legs/feet still had “mossy” trophic 
changes evident across the treatment groups, compared to 22.2% reported by Sikorski et al, 
after a year of treatment14. This indicates that a longer period of continuous treatment is 
probably needed to reduce trophic changes. It is remarkable that an intervention comprising 
water, soap and petrolatum can bring about these improvements at all and, once again, 
indicates the importance of improving and maintaining SBF in the treatment regimen.  
 
In this study, a reduction in the number of wounds in both groups was associated with a 
reduction in the work days lost due to ADL. This is important, as most of those in this study 
were subsistence farmers, so any income loss would have significant economic effects. 
Indeed, it is estimated that Ethiopia loses approximately 200 million USD annually through 
lost work days due to podoconiosis10.  
 
This current study and Sikorski et als.14 both demonstrate the utility of simple treatment 
regimes in significantly improving quality of life in those with podoconiosis (evidenced by 
improved DLQI scores). We hypothesise that this is likely due to a combination of the skin 
care and attention received in treatment sites, the visible improvement in leg/foot condition, a 
reduction in ADL and odour and a concomitant decrease in stigma and ostracism.  
 
The significant difference in TEWL reduction in right legs compared to left legs and greater 
reduction in circumference of the right foot may have been due to more attention being given 
to the right leg during treatment or to this leg being used more than the left when walking (in 
those with a right side preference). Exercise is known to improve circulation and venous 
return thus reducing oedema6. It may also have been explained by the anatomical and 
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physiological differences between legs which impair left leg venous and lymphatic 
drainage25.  
 
Finally, in this study, we incorporated 2.0% glycerine (v/v) into only 1 litre of wash/soaking 
water (versus current 6 litres). Participants were able to follow instructions and use the new 
treatment protocol effectively. This new regimen not only conserves the precious resource of 
water, but also minimises the glycerine requirement.  
 
In summary, the results of this study support our hypothesis that current podoconiosis 
treatment regimens can be enhanced further by increasing the water-binding potential of the 
SC with the humectant, glycerine. This is widely available in Ethiopia, even in rural settings, 
at low cost. The addition of glycerine to a water soak may be effective in a wide variety of 
other skin diseases, including lymphoedematous conditions such as lymphatic filariasis, 
where compromised SBF is indicated and skin care is critical. Glycerine use in podoconiosis 
treatment is currently being considered for implementation by APIDO. Further research is 
needed to investigate lower dilutions of glycerine and different soaking methods (e.g., 
wrapping technique), to further reduce cost, water usage and increase efficiency.  
Study limitations 
Podoconiosis diagnosis was based on participants living at high altitude, with volcanic soil, 
high rainfall, displaying clinical manifestations of the disease. No differential diagnosis was 
made to exclude those with swelling of the lower leg due to other diseases such as lymphatic 
filariasis, liver or heart failure. Although groups were matched as far as possible, there may 
have been other confounding factors influencing the results that are not identified. Although 
participants were not supervised daily to ensure treatment adherence, improvements in SBF 
would not have been achieved without some level of compliance.  
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Figure legends 
Picture 1. Feet of patients presenting with oedema, hyperkeratosis, nodules, fused toes, mossy 
changes and ulceration due to ill-fitting shoes.  
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Figure 1. Development and cycle of progression of lymphoedema in podoconiosis. 
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Table 1. Demographic profile of all participants at baseline (n=193) 
 
Age (years) Occupation Time to onset (years) Shoes worn in previous week  
18-29,  28% (54)  farmers, 46.1% (89) >1 year, 1% (2)  barefoot, 9.4% (18)  
30-39, 15.8% (33) housewives, 42.5% (82) 1-2 years, 24.4% (47) hard plastic sandals, 62.2% (120) 
40-49, 22.5% (47) students, 7.3% (14) 3-4 years, 25.4% (49)  canvas shoes, 12.4% (24)  
50-59, 15.3% (32) others, 4.1% (8) e.g. 
servants and merchants   
5-6 years, 24.4%, (47) other enclosed shoes,10.4% (20) 
60-69, 22 (10.5%)   7-8 years, 11.9% (23)  open sandals made with tyres, 4.7% (9) 
>70, 2.6% (5)  9-10 years 9.3% (18)  other sandals, 1% (2)  
  11-12 years.2.1% (4)   
  >12 years 1.6% (3)   
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Table 2. Mean TEWL (gm2h) across all participants measured at different anatomical sites 
within podoconiosis-affected legs/feet, at baseline.  
 
Site on the lower leg  Mean TEWL (gm2h) right leg 
1st Visit  
Mean TEWL (gm2h) left leg 
 1st Visit  
Top  13.08  13.40  
Mid-point 14.29  15.02  
Base 16.62  17.17  
Top of Foot  22.41  22.75  
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Table 3. TEWL (gm2h) - estimated group differences at Visits 2, 3, 4.  
 
Anatomical 
site  
Estimated 
group 
difference 
(gm2h) 
Standard 
Error 
t df p 95% CI for the 
group difference 
Top of outer 
lower leg 
1.582  0.296 5.341 89.347 <0.001  (0.997, 2.164) 
Mid-point of 
outer lower leg 
1.684  0.346 4.871 189.789 <0.001 (1.0023, 2.367) 
Base of outer 
lower leg 
1.970  0.386 5.111 189.620 <0.001 (1.210, 2.731) 
Middle of top of 
foot  
1.751  0.390 3.154 189.580 0.002 (0.656, 2.846) 
 
 
 
 
  
 
 
 Page 22 
 
Figure 2. CONSORT 2010 Flow Diagram 
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Discontinued intervention) (n=0) 
Allocated to experimental intervention (n=96) 
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Figure 3. Top of foot - difference over time between groups in mean TEWL (gm2h) 
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Table 4.  Mean SC hydration (Moisture Meter SC; AU) (arbitrary units) across all 
participants measured at different anatomical sites within podoconiosis affected legs/feet at 
baseline 
 
 
Point on the lower leg  Mean SC hydration right lower leg Mean SC hydration left lower leg 
Top  9.33 9.54 
Mid-point 9.03 9.23 
Base 8.51 8.55 
Top of foot  8.49 8.62 
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Table 5. SC hydration (arbitrary units) - estimated group differences at Visits 2, 3 and 4  
 
Anatomical 
site  
Estimated 
group 
difference 
Standard 
Error 
T df  p 95% CI for the group 
difference 
Top of lower 
outer leg 
-2.075 0.515 -4.236 165.310 <0.001 (-3.042, -1.108) 
Mid-point lower 
outer leg  
-1.658 0.467 3.549 180.923 <0.001 (-2.581, -0.736) 
Base lower outer 
leg 
-1.641 0.473 - 3.471 186.308 0.001 (-2.574, -0.708) 
Top of foot  -2.041 0.572 -3.565 186.739 <0.001 (-3.168, -0.911) 
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Figure 4. Top of foot - difference over time between groups in mean SC hydration (arbitrary 
units) 
 
 
 
 
 
 
 
 
 
